UK to consider first OTC benign prostate hyperplasia therapy
This article was originally published in Scrip
Executive Summary
The UK medicines regulator, theMHRA, looks set to switch the prescription status ofBoehringer Ingelheim's Flomax (tamsulosin). This would make it the UK's first pharmacy-only medicine for the treatment of benign prostatic hyperplasia (BPH), although there are herbal remedies available OTC for the symptomatic relief of male short-term urinary discomfort.